We integrate generative AI with transcriptomic big data to build AI models capable of understanding biological semantics, advancing precision medicine in complex diseases like cancer.
We integrate generative AI with transcriptomic big data to build AI models capable of understanding biological semantics, advancing precision medicine in complex diseases like cancer.
We integrate generative AI with transcriptomic big data to build AI models capable of understanding biological semantics, advancing precision medicine in complex diseases like cancer.
Dual-patent technology revolutionizes sequencing performance
BIRT achieves multiplex sequencing breakthroughs, while PERD enables enzyme-free rRNA removal.
Unlocking the "black box" of FFPE samples
A single 4µm FFPE section now delivers the results previously requiring multiple traditional sections.
One-stop coverage of the research workflow
Comprehensive professional services: from sample to AI insights and final reports.
Dual-patent technology revolutionizes sequencing performance
BIRT achieves multiplex sequencing breakthroughs, while PERD enables enzyme-free rRNA removal.
Unlocking the "black box" of FFPE samples
A single 4µm FFPE section now delivers the results previously requiring multiple traditional sections.
One-stop coverage of the research workflow
Comprehensive professional services: from sample to AI insights and final reports.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
BIRT+PERD RNA-seq
Dual patents provide strong support
Dual patents provide strong support
Low-quality sample processing
Low-quality sample processing
Low-input breakthrough
Low-input breakthrough
High-throughput upgrade
High-throughput upgrade
To break through the limitations of traditional technologies, Biosheng AI has integrated two self-developed core technologies to create a brand-new RNA sequencing solution. This solution significantly enhances detection throughput via BIRT for multiplex sequencing, while utilizing PERD to efficiently remove ribosomal RNA without the use of enzymes, thereby avoiding the increased costs and potential data bias associated with enzymatic steps from the source.
K-Dense Multi-Module AI Services
End-to-end service for the entire workflow
End-to-end service for the entire workflow
End-to-end service for the entire workflow
End-to-end service for the entire workflow
Reliable and traceable results
Reliable and traceable results
Reliable and traceable results
Reliable and traceable results
Biosheng AI introduces a one-stop, multi-module AI service portfolio. Centered on the synergy of these modules, the service covers the entire workflow: high-throughput RNA-seq sequencing, bioinformatics analysis, AI model training, and report writing. This solution both acquires comprehensive transcriptomic data through professional sequencing technology and leverages AI modules for deep data interpretation and model construction. The outcomes are delivered via customized reports, providing efficient, complete services for transcriptomic research projects and boosting both research efficiency and the quality of results.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Promoting the clinical application and innovation of precision medicine and intelligent diagnostics in China.
Rooted in China and powered by the Biostate AI tech foundation, Biosheng AI launched in 2025 in Shanghai. We focus on fusing Generative AI with life sciences, driving the local application and innovation of precision medicine and smart diagnostics through advanced technology.
Advancing Precision Medicine Innovation in China.
Biosheng AI(founded 2025, Shanghai) leverages the Biostate AI foundation to fuse Generative AI with life sciences, driving innovation in precision medicine and smart diagnostics across China.
Advancing Precision Medicine Innovation in China.
Biosheng AI(founded 2025, Shanghai) leverages the Biostate AI foundation to fuse Generative AI with life sciences, driving innovation in precision medicine and smart diagnostics across China.
Advancing Precision Medicine Innovation in China.
Biosheng AI(founded 2025, Shanghai) leverages the Biostate AI foundation to fuse Generative AI with life sciences, driving innovation in precision medicine and smart diagnostics across China.
BIRT+PERD RNA Sequencing (RNA-seq) Technology
Dual Patents
Problem Samples
Low-input
HTP
Biosheng AI integrates two core technologies (BIRT and PERD) into a new RNA sequencing solution. This approach enhances throughput via multiplex sequencing and efficiently removes rRNA without enzymes, cutting costs and eliminating enzymatic bias.
K-Dense Multi-Module AI Services
End-to-end service for the entire workflow.
End-to-end service for the entire workflow.
End-to-end service for the entire workflow.
End-to-end service for the entire workflow.
Reliable and traceable results
Reliable and traceable results
Reliable and traceable results
Reliable and traceable results
Biosheng AI introduces a one-stop, multi-module AI service portfolio. Centered on the synergy of these modules, the service covers the entire workflow: high-throughput RNA-seq sequencing, bioinformatics analysis, AI model training, and report writing. This solution both acquires comprehensive transcriptomic data through professional sequencing technology and leverages AI modules for deep data interpretation and model construction. The outcomes are delivered via customized reports, providing efficient, complete services for transcriptomic research projects and boosting both research efficiency and the quality of results.
BIRT+PERD RNA-seq
Dual patents provide strong support
Dual patents provide strong support
Low-quality sample processing
Low-quality sample processing
Low-input breakthrough
Low-input breakthrough
High-throughput upgrade
High-throughput upgrade
To break through the limitations of traditional technologies, Biosheng AI has integrated two self-developed core technologies to create a brand-new RNA sequencing solution. This solution significantly enhances detection throughput via BIRT for multiplex sequencing, while utilizing PERD to efficiently remove ribosomal RNA without the use of enzymes, thereby avoiding the increased costs and potential data bias associated with enzymatic steps from the source.
K-Dense Multi-Module AI Services
Full Service
Minimize Time
Full Traceability
Multi-scenario AI
Biosheng AI offers a one-stop, multi-module AI service portfolio. We cover the entire workflow—from high-throughput RNA-seq and bioinformatics to AI training and reporting—providing efficient, complete services for transcriptomic research to boost efficiency and results.